Sarclisa (isatuximab-irfc)
Also marketed as Sarclisa Escena. An approved treatment for Multiple Myeloma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Isatuximab-irfc wherever you encounter it, plus the key facts at a glance.
- Generic name
- Isatuximab-irfc
- Brand names
- Sarclisa, Sarclisa Escena
- Development code
- SAR650984
- Drug class
- CD38-directed cytolytic antibody (anti-CD38 monoclonal antibody)
- Manufacturer
- Sanofi (sanofi-aventis U.S. LLC)
- How it's taken
- Intravenous infusion (Sarclisa) or injection under the skin of the belly (Sarclisa Escena), weekly at first and later every 2 or 4 weeks
Sarclisa (isatuximab-irfc) is an anti-CD38 antibody given with other myeloma medicines to adults with newly diagnosed or previously treated multiple myeloma[1].
- The FDA first approved Sarclisa, an infusion into a vein, on March 2, 2020, and approved Sarclisa Escena, an injection under the skin, on July 9, 2026[3][4].
- In the IMROZ trial of 446 adults who could not have a stem cell transplant, adding Sarclisa to bortezomib, lenalidomide and dexamethasone lowered the risk of the myeloma worsening or death (hazard ratio 0.60)[1].
- Sarclisa has no boxed warning, and its main label warnings are infusion or injection reactions, serious infections, low white blood cells and new second cancers[1][2].
- Sarclisa is not approved on its own, and it is not approved for people with newly diagnosed myeloma who are eligible for a stem cell transplant[1].
We'll email you when Sarclisa's FDA label changes, when the FDA acts on it, and when new trials for Multiple Myeloma open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Isatuximab-irfc fits
Sarclisa has 3 myeloma uses, each in combination[1]. For newly diagnosed myeloma in adults who cannot have an autologous stem cell transplant, it is given with bortezomib, lenalidomide and dexamethasone[1]. For relapsed or refractory myeloma after 1 to 3 prior lines, it is given with carfilzomib and dexamethasone[1]. With pomalidomide and dexamethasone, the 2 forms have slightly different wording. The Sarclisa infusion label requires at least 2 prior therapies including lenalidomide and a proteasome inhibitor, while the Sarclisa Escena label requires at least 1 prior line including those 2 medicines[1][2].
How Isatuximab-irfc works
Sarclisa is a monoclonal antibody, a lab-made protein that locks onto one specific target[1]. Its target is CD38, a protein found on the surface of myeloma cells and other blood-forming and tumor cells[1].
Once attached, the label says Sarclisa works in several ways[1]:
In lab studies, Sarclisa combined with pomalidomide killed more myeloma cells than Sarclisa alone, and in an animal model of myeloma the combination had more anti-tumor activity than either medicine alone[1]. Sarclisa is approved only in combination with other myeloma medicines[1].
Sarclisa and Sarclisa Escena contain the same antibody, isatuximab-irfc[1][2]. Sarclisa is a weight-based infusion into a vein, while Sarclisa Escena is a fixed dose injected under the skin of the belly[1][2].
Side effects and safety
- Infusion-related reactions (Sarclisa). Occurred in 35% across 3 trials, grade 3 or 4 in 1.2%; can be life-threatening and fatal outcomes have been reported; premedication is required and severe reactions stop treatment permanently.
- Hypersensitivity and administration reactions (Sarclisa Escena). Whole-body reactions in 3.2% and injection site reactions in 9% across 411 people; a grade 4 reaction stops treatment permanently.
- Infections. Serious infections in 46% and fatal infections in 4.7% with Sarclisa infusions; serious infections in 29% and fatal in 2.9% with Sarclisa Escena.
- Neutropenia. Low neutrophils in 81% (grade 3 or 4 in 52%) with Sarclisa and 86% (grade 3 or 4 in 66%) with Sarclisa Escena; doses may be delayed.
- Second primary malignancies. New cancers in 12% of people on Sarclisa infusions in trials, most often skin cancers; the label advises monitoring.
- Laboratory test interference. Can cause a false positive indirect Coombs test for about 6 months and can interfere with M-protein tests; blood type and screen is done before the first dose.
- Embryo-fetal toxicity. Can harm an unborn baby; birth control during treatment and for 5 months (Sarclisa) or 7 months (Sarclisa Escena) after the last dose.
- Vital signs throughout each Sarclisa infusion
- Complete blood counts periodically during treatment
- Signs and symptoms of infection before and during treatment
- Blood type and screen before the first dose, and telling the blood bank about treatment
- Watching for new cancers during and after treatment
- Pregnancy status before treatment
Sarclisa does not carry a boxed warning[1]. The label's warnings cover infusion-related reactions, infections, low neutrophils (a type of white blood cell), second primary cancers, interference with blood bank and myeloma lab tests, and harm to an unborn baby[1].
With Sarclisa infusions, across the ICARIA-MM, IKEMA and IMROZ trials (592 people)[1]:
- Infusion-related reactions occurred in 35%, mostly grade 2, and 92% of those happened during the first infusion[1]
- Serious infections occurred in 46%, and fatal infections in 4.7%, with pneumonia the most common serious infection[1]
- Low neutrophils occurred in 81%, grade 3 or 4 in 52%[1]
- Second primary cancers, mostly skin cancers and other solid tumors, occurred in 12%[1]
The June 2026 label states that infusion reactions can be life-threatening and that fatal outcomes have been reported[1]. Severe signs included cardiac arrest, high or low blood pressure, bronchospasm and swelling[1].
With Sarclisa Escena injections, across the IRAKLIA, IZALCO and IsaSoCut studies (411 people), whole-body administration reactions occurred in 3.2% and injection site reactions in 9%[2]. Serious infections occurred in 29% and fatal infections in 2.9%[2].
Sarclisa binds to red blood cells, so it can make a routine blood bank test (the indirect Coombs test) falsely positive for about 6 months after the last infusion[1]. It can also show up on the tests used to track M-protein, which can make a complete response harder to confirm in people with IgG kappa myeloma[1]. The Sarclisa label advises birth control during treatment and for 5 months after the last dose, and the Sarclisa Escena label says 7 months[1][2].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Isatuximab-irfc
Sarclisa and Sarclisa Escena are always given with other myeloma medicines by a healthcare professional[1][2]. The 2 forms have different doses and routes, and the label tells care teams to check which form is being given[2].
Sarclisa (into a vein)[1]:
- Dose: 10mg/kg of actual body weight as an intravenous infusion[1]
- With pomalidomide or carfilzomib: weekly in the first 28-day cycle, then every 2 weeks[1]
- With bortezomib, lenalidomide and dexamethasone: weekly in the first 42-day cycle, every 2 weeks through cycle 17, then every 4 weeks from cycle 18[1]
- The first infusion starts at 25mL per hour and speeds up gradually only if there is no reaction; from the third infusion on, infusions run at 200mL per hour[1]
Sarclisa Escena (under the skin)[2]:
- Dose: a fixed 1,400mg injected into the belly, either by hand with a syringe over about 6 minutes or with the CirCLIQ on-body injector, which took a median of 13 minutes in IRAKLIA[2]
- With bortezomib, lenalidomide and dexamethasone: weekly in cycle 1, every 2 weeks in cycles 2 to 12, then every 4 weeks from cycle 13[2]
- People on Sarclisa infusions may switch to Sarclisa Escena after finishing the first cycle[2]
Before each dose, people receive medicines to lower the risk of reactions: dexamethasone, acetaminophen and diphenhydramine, plus an H2 blocker for infusions or a leukotriene blocker in the first Sarclisa Escena cycle[1][2]. Treatment continues until the myeloma worsens or side effects become unacceptable, and the label recommends no dose reductions, only delays[1].
Sarclisa has no REMS of its own, but the label notes that pomalidomide and lenalidomide, which are often part of the combination, are available only through REMS programs[1][2].
Availability and cost
Only available as the brand-name product.
Help paying for Sarclisa
With private insurance, the drugmaker's copay card can lower what you pay for Sarclisa. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 5 charity funds for Multiple Myeloma, 1 was open on October 26, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
People with commercial or private insurance could pay as little as $0 for copays, coinsurance and deductibles for Sarclisa or Sarclisa Escena through the CareASSIST Copay Program, subject to a program maximum per patient per calendar year. Not valid for prescriptions covered by Medicare, Medicaid, VA, DoD, TRICARE or similar federal or state programs.
For: private insurance · source - Free medicine program
People with government insurance, no insurance or a gap in insurance coverage may qualify to receive Sarclisa or Sarclisa Escena at no cost through the CareASSIST Patient Assistance Program. Free product is provided by Sanofi Cares North America, a charitable organization of Sanofi.
For: Medicare, Medicaid, no insurance, underinsured · source - Insurance and case manager help
A dedicated Case Manager helps with the insurance process, financial assistance options, alternate funding programs and connections to patient support organizations. Enrollment is free, online or by fax to 1-855-411-9689. Call 1-833-930-2273, Monday through Friday, 9 AM to 6 PM ET; help is available in Spanish.
For: private insurance, Medicare, Medicaid, no insurance · source
Good to know: CareASSIST is a Sanofi program only for people prescribed Sarclisa or Sarclisa Escena for an approved use. Sanofi says a Case Manager usually reaches out within 1 to 2 business days after enrollment, and the program can be changed or ended at any time without notice. The page does not state the dollar amount of the yearly copay maximum.
Charity funds for Multiple Myeloma
- From a charity · HealthWell FoundationMultiple Myeloma (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
Clinical trial results
IMROZ (NCT03319667) randomized 446 adults with newly diagnosed myeloma who could not have a stem cell transplant to Sarclisa plus bortezomib, lenalidomide and dexamethasone, or the same 3 medicines alone[1][10]. Results at a median follow-up of 60 months, from the label[1]:
- Progression-free survival: median not reached with Sarclisa versus 54.3 months, hazard ratio 0.60[1]
- Complete response or better: 75% versus 64%[1]
- No detectable myeloma (MRD negativity) with a complete response: 55% versus 41%[1]
- Deaths: 26% versus 32.6%, with median overall survival not reached in either group[1]
The first IMROZ results were published in the New England Journal of Medicine in 2024[6].
ICARIA-MM (NCT02990338) enrolled 307 people who had at least 2 prior therapies including lenalidomide and a proteasome inhibitor[1][7]. Sarclisa plus pomalidomide and dexamethasone had a median progression-free survival of 11.5 months versus 6.5 months without Sarclisa (hazard ratio 0.596), and 60.4% responded versus 35.3%[1]. Final median overall survival was 24.6 versus 17.7 months (hazard ratio 0.776)[1].
IKEMA (NCT03275285) enrolled 302 people after 1 to 3 prior lines[1][8]. At the final analysis, median progression-free survival was 41.7 months with Sarclisa plus carfilzomib and dexamethasone versus 20.8 months without Sarclisa (hazard ratio 0.594)[1].
IRAKLIA (NCT05405166) compared Sarclisa Escena under the skin with Sarclisa infusions, each with pomalidomide and dexamethasone, in 531 people[2][11]. The response rate was 71.1% with Sarclisa Escena and 70.5% with infusions, which met the trial's test for being no worse[2][9].
Development history
Sarclisa's myeloma approvals, from Drugs@FDA and FDA letters[3]:
- March 2, 2020: first approval, with pomalidomide and dexamethasone after at least 2 prior therapies, based on ICARIA-MM[3][1]
- March 31, 2021: with carfilzomib and dexamethasone after 1 to 3 prior lines, based on IKEMA[3][1]
- September 20, 2024: with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma when a transplant is not an option, based on IMROZ[3][1]
- July 9, 2026: Sarclisa Escena, a new form for injection under the skin, approved for the same 3 combinations, with its pomalidomide use starting after at least 1 prior line instead of 2[4][5]
Drugs@FDA also lists efficacy supplements approved on November 1, 2023 and October 25, 2024[3]. The current label includes final ICARIA-MM overall survival, final IKEMA progression-free survival and IKEMA overall survival results[1]. A June 2026 update revised the infusion reaction warning, which now says fatal outcomes have been reported[1][3].
Sanofi announced the Sarclisa Escena approval on July 10, 2026, and called it the first cancer medicine given with an on-body injector[5]. No Sarclisa indication has been withdrawn.
Explore Multiple Myeloma trials
Other Multiple Myeloma treatments
Sarclisa and Darzalex (daratumumab) are the 2 FDA-approved anti-CD38 antibodies for myeloma, and both now come in a form given under the skin, Sarclisa Escena and Darzalex Faspro[2][12]. No trial has compared Sarclisa with daratumumab directly. Both are given with backbone medicines such as proteasome inhibitors (bortezomib, carfilzomib) and immunomodulatory drugs (lenalidomide, pomalidomide)[1][12]. In IRAKLIA, 14% of people in the Sarclisa Escena group had received daratumumab before[2].
Common questions about Isatuximab-irfc
▸What is Isatuximab-irfc (Sarclisa)?
Sarclisa (isatuximab-irfc) is an anti-CD38 antibody given with other myeloma medicines to adults with newly diagnosed or previously treated multiple myeloma[1]. The FDA first approved Sarclisa, an infusion into a vein, on March 2, 2020, and approved Sarclisa Escena, an injection under the skin, on July 9, 2026[3][4]. In the IMROZ trial of 446 adults who could not have a stem cell transplant, adding Sarclisa to bortezomib, lenalidomide and dexamethasone lowered the risk of the myeloma worsening or death (hazard ratio 0.60)[1]. Sarclisa has no boxed warning, and its main label warnings are infusion or injection reactions, serious infections, low white blood cells and new second cancers[1][2]. Sarclisa is not approved on its own, and it is not approved for people with newly diagnosed myeloma who are eligible for a stem cell transplant[1].
▸How does Isatuximab-irfc work?
Sarclisa is a monoclonal antibody, a lab-made protein that locks onto one specific target[1]. Its target is CD38, a protein found on the surface of myeloma cells and other blood-forming and tumor cells[1].
Once attached, the label says Sarclisa works in several ways[1]:
- It triggers myeloma cells to self-destruct (apoptosis)[1]
- It flags them for immune cells and blood proteins that kill or swallow marked cells, called ADCC, ADCP and CDC[1]
- It switches on natural killer cells and dampens CD38-positive regulatory T cells, which normally hold the immune response back[1]
In lab studies, Sarclisa combined with pomalidomide killed more myeloma cells than Sarclisa alone, and in an animal model of myeloma the combination had more anti-tumor activity than either medicine alone[1]. Sarclisa is approved only in combination with other myeloma medicines[1].
Sarclisa and Sarclisa Escena contain the same antibody, isatuximab-irfc[1][2]. Sarclisa is a weight-based infusion into a vein, while Sarclisa Escena is a fixed dose injected under the skin of the belly[1][2].
▸What are the side effects of Isatuximab-irfc?
Sarclisa does not carry a boxed warning[1]. The label's warnings cover infusion-related reactions, infections, low neutrophils (a type of white blood cell), second primary cancers, interference with blood bank and myeloma lab tests, and harm to an unborn baby[1].
With Sarclisa infusions, across the ICARIA-MM, IKEMA and IMROZ trials (592 people)[1]: Infusion-related reactions occurred in 35%, mostly grade 2, and 92% of those happened during the first infusion[1] Serious infections occurred in 46%, and fatal infections in 4.7%, with pneumonia the most common serious infection[1] Low neutrophils occurred in 81%, grade 3 or 4 in 52%[1] Second primary cancers, mostly skin cancers and other solid tumors, occurred in 12%[1]
The June 2026 label states that infusion reactions can be life-threatening and that fatal outcomes have been reported[1]. Severe signs included cardiac arrest, high or low blood pressure, bronchospasm and swelling[1].
With Sarclisa Escena injections, across the IRAKLIA, IZALCO and IsaSoCut studies (411 people), whole-body administration reactions occurred in 3.2% and injection site reactions in 9%[2]. Serious infections occurred in 29% and fatal infections in 2.9%[2].
Sarclisa binds to red blood cells, so it can make a routine blood bank test (the indirect Coombs test) falsely positive for about 6 months after the last infusion[1]. It can also show up on the tests used to track M-protein, which can make a complete response harder to confirm in people with IgG kappa myeloma[1]. The Sarclisa label advises birth control during treatment and for 5 months after the last dose, and the Sarclisa Escena label says 7 months[1][2].
▸How is Isatuximab-irfc taken?
Sarclisa and Sarclisa Escena are always given with other myeloma medicines by a healthcare professional[1][2]. The 2 forms have different doses and routes, and the label tells care teams to check which form is being given[2].
Sarclisa (into a vein)[1]:
- Dose: 10mg/kg of actual body weight as an intravenous infusion[1]
- With pomalidomide or carfilzomib: weekly in the first 28-day cycle, then every 2 weeks[1]
- With bortezomib, lenalidomide and dexamethasone: weekly in the first 42-day cycle, every 2 weeks through cycle 17, then every 4 weeks from cycle 18[1]
- The first infusion starts at 25mL per hour and speeds up gradually only if there is no reaction; from the third infusion on, infusions run at 200mL per hour[1]
Sarclisa Escena (under the skin)[2]:
- Dose: a fixed 1,400mg injected into the belly, either by hand with a syringe over about 6 minutes or with the CirCLIQ on-body injector, which took a median of 13 minutes in IRAKLIA[2]
- With bortezomib, lenalidomide and dexamethasone: weekly in cycle 1, every 2 weeks in cycles 2 to 12, then every 4 weeks from cycle 13[2]
- People on Sarclisa infusions may switch to Sarclisa Escena after finishing the first cycle[2]
Before each dose, people receive medicines to lower the risk of reactions: dexamethasone, acetaminophen and diphenhydramine, plus an H2 blocker for infusions or a leukotriene blocker in the first Sarclisa Escena cycle[1][2]. Treatment continues until the myeloma worsens or side effects become unacceptable, and the label recommends no dose reductions, only delays[1]. Sarclisa has no REMS of its own, but the label notes that pomalidomide and lenalidomide, which are often part of the combination, are available only through REMS programs[1][2].
▸Is Isatuximab-irfc FDA approved?
Yes, Isatuximab-irfc (Sarclisa) is FDA approved (2020) for the treatment of Multiple Myeloma.
▸What is the difference between Sarclisa and Sarclisa Escena?
Both contain isatuximab-irfc, but Sarclisa is an infusion into a vein and Sarclisa Escena is an injection under the skin of the belly[1][2].
Dose: Sarclisa is 10mg/kg by weight; Sarclisa Escena is a fixed 1,400mg[1][2].
How: Sarclisa Escena is given by hand with a syringe over about 6 minutes, or with the CirCLIQ on-body injector, which took a median of 13 minutes in IRAKLIA[2].
Trial: In IRAKLIA, response rates were 71.1% with Sarclisa Escena and 70.5% with infusions[2].
Switching: The label allows a switch after the first cycle of infusions[2].
Source: Sarclisa and Sarclisa Escena prescribing information (DailyMed)
▸Is Sarclisa chemotherapy?
No, Sarclisa is a monoclonal antibody that targets CD38 on myeloma cells, not a traditional chemotherapy[1].
How it works: It kills myeloma cells directly and marks them for the immune system[1].
Combinations: It is always given with other myeloma medicines, such as pomalidomide, carfilzomib, bortezomib or lenalidomide, with dexamethasone[1].
Source: Sarclisa prescribing information (DailyMed)
▸How long does a Sarclisa infusion take?
The label does not give a fixed time; it depends on the infusion rate, which starts slow and speeds up only if there is no reaction[1].
First infusion: Starts at 25mL per hour, with a maximum of 150mL per hour[1].
Later infusions: Run at 200mL per hour from the third infusion[1].
Before: Premedicines are given 15 to 60 minutes before each infusion[1].
Source: Sarclisa prescribing information (DailyMed)
▸Can Sarclisa affect a blood transfusion?
Yes, Sarclisa can make the indirect Coombs test used to match blood falsely positive for about 6 months after the last infusion[1].
Before treatment: The label calls for blood type and screen tests before the first dose[1].
Blood bank: The label says to tell the blood bank about treatment, and the lab can work around the interference[1].
Blood type: ABO and RhD typing are not affected[1].
Source: Sarclisa prescribing information (DailyMed)
▸How much does Sarclisa cost?
A list price is not stated on the label, and Trial Friend does not publish a price it cannot confirm.
Commercial insurance: Sanofi says eligible patients could pay as little as $0 through the CareASSIST Copay Program, subject to a yearly maximum[13].
Other coverage: Sanofi says people with government insurance, no insurance or a coverage gap may qualify for free medicine through its Patient Assistance Program[13].
Source: Sanofi CareASSIST FAQs
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed (sanofi-aventis U.S. LLC) · 2026-07. SARCLISA (isatuximab-irfc) injection, for intravenous use, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0473462-6f9d-4eca-a5bf-8620aea68e8a
- U.S. National Library of Medicine, DailyMed (sanofi-aventis U.S. LLC) · 2026-07. SARCLISA ESCENA (isatuximab-irfc) injection, for subcutaneous use, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07730e8c-1340-4d30-8d71-e20f850db8da
- U.S. Food and Drug Administration · 2026-06-26. Drugs@FDA: SARCLISA, BLA 761113, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761113
- U.S. Food and Drug Administration · 2026-07-09. Drugs@FDA: SARCLISA ESCENA, BLA 761445, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761445
- Sanofi · 2026-07-10. Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector. https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-10-12-35-09-3325483
- New England Journal of Medicine · 2024-10-31. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. https://doi.org/10.1056/NEJMoa2400712
- The Lancet · 2019-12-07. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM). https://doi.org/10.1016/S0140-6736(19)32556-5
- The Lancet · 2021-06-19. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. https://doi.org/10.1016/S0140-6736(21)00592-4
- Journal of Clinical Oncology · 2025-08. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. https://doi.org/10.1200/JCO-25-00744
- ClinicalTrials.gov · 2026-11. A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (IMROZ). https://clinicaltrials.gov/study/NCT03319667
- ClinicalTrials.gov · 2026-11. SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA). https://clinicaltrials.gov/study/NCT05405166
- U.S. National Library of Medicine, DailyMed (Janssen Biotech, Inc.) · 2026-09. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0
- Sanofi · 2026-07. Explore Patient FAQs for CareASSIST. https://www.sanoficareassist.com/faqs